HomeEndocrinologySome SA firms start subsidising employees’ weight-loss meds

Some SA firms start subsidising employees’ weight-loss meds

With obesity costing South Africa around R33bn annually – and being linked to more than 200 (expensive) health complications – some local companies are beginning to cover the costs of weight-loss medication for employees, reports Weekend Argus.

They are viewing medically supervised obesity treatment as a worthwhile investment in workforce health, productivity and reduced absenteeism, according to Obiflex, a doctor-led health management programme that enables companies to fund GLP-1 treatment in full or in part through payroll deductions.

Nearly half of South African adults are overweight or obese, said Shaun Barns, co-founder and chief executive of Obiflex, and to curb this “pandemic”, an affordable, effective medical and lifestyle intervention is vital, he added.

Research across 26 European countries, presented at the European Congress on Obesity, found that obese employees were up to 2.2 times more likely to be absent from work for more than a week than their healthy-weight colleagues.

Meanwhile, a survey of 600 obese adults across six countries, published in Obesity Science & Practice, found that 59% of employed respondents said their weight negatively affected their work, while 46% said it limited their career prospects.

Dr Shay Ganesh, head of innovation at Medihelp Medical Scheme, said traditional workplace wellness programmes often struggled to translate employee participation into measurable health outcomes.

In South Africa, registered GLP-1 weight-loss medicines typically cost between R3 000 and R6 000 a month, excluding medical consultations. Most medical schemes contribute only about 50% towards the medication for diabetic members, leaving the treatment unaffordable for many employees.

But, Barns said, employers are now starting to cover or subsidise the costs, following an approach increasingly adopted by international companies.

Bank of America, for example, spends about $250m annually on GLP-1 cover for more than 200 000 employees.

Locally, Medihelp, one of South Africa’s largest open medical schemes, will fully subsidise eligible employees for three months, with a new group joining the programme as each participating group completes its treatment.

Medihelp chief executive and principal officer Varsha Vala said the organisation was concerned about employees turning to illicit treatments rather than medicines approved by the South African Health Products Regulatory Authority (SAHPRA).

Medihelp was exploring deeper partnerships with Obiflex to strengthen its Return on Health proposition in the corporate market, she added.

Alternative-investment company Grovest is also subsidising treatment for its employees, while several large financial services organisations are investigating the programme.

Under Obiflex’s model, employees can choose between three-month and six-month payment plans. On the three-month plan, employees would typically pay R1 499 a month over five months, amounting to R7 495 in total. On the six-month plan, monthly instalments are R1 999. If an employer contributes R300 towards each instalment, the employee pays R1 699 a month.

Where the employer covers the full amount, as Medihelp is doing, employees pay nothing.

 

Weekend Argus PressReader article – Employers begin to subsidise weight loss meds for staff (Open access)

 

See more from MedicalBrief archives:

 

Germany mulls reimbursing weight-loss drugs costs

 

Why I think weight loss drugs are not the answer – US obesity expert

 

Discounted Ozempic copy unlikely to be covered by medical aids

MedicalBrief — our free weekly e-newsletter

We'd appreciate as much information as possible, however only an email address is required.